APLS vs. ROIV, RVMD, ELAN, BPMC, BBIO, VRNA, TLX, TGTX, GRFS, and LNTH
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Grifols (GRFS), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.
Apellis Pharmaceuticals vs.
Roivant Sciences (NASDAQ:ROIV) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, community ranking, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.
In the previous week, Roivant Sciences had 2 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 12 mentions for Roivant Sciences and 10 mentions for Apellis Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.18 beat Apellis Pharmaceuticals' score of 1.12 indicating that Roivant Sciences is being referred to more favorably in the media.
Apellis Pharmaceuticals has a net margin of -34.97% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Apellis Pharmaceuticals' return on equity.
Apellis Pharmaceuticals received 296 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.87% of users gave Roivant Sciences an outperform vote while only 66.42% of users gave Apellis Pharmaceuticals an outperform vote.
Roivant Sciences has higher earnings, but lower revenue than Apellis Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Roivant Sciences presently has a consensus target price of $17.50, indicating a potential upside of 62.87%. Apellis Pharmaceuticals has a consensus target price of $39.89, indicating a potential upside of 134.88%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Roivant Sciences.
64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Roivant Sciences has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Summary
Roivant Sciences beats Apellis Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:APLS) was last updated on 5/28/2025 by MarketBeat.com Staff
